Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533956 | 0.85 | TRPV4 (0.68) | KMT2AUSP2GAAMEN1SMN1; SMN2 | |
| SCHEMBL18969789 | 0.83 | TSHR (0.54) | KMT2AUSP2GAAMEN1SMN1; SMN2 | |
| SCHEMBL12180426 | 0.82 | SMN1; SMN2 (0.67) | KMT2AUSP2GAAMEN1SMN1; SMN2 | |
| SCHEMBL5012595 | 0.81 | SMN1; SMN2 (0.59) | KMT2AUSP2GAASMN1; SMN2TSHR | |
| SCHEMBL13290942 | 0.81 | KMT2A (0.60) | KMT2AUSP2GAAMEN1SMN1; SMN2 | |
| SCHEMBL407215 | 0.81 | L3MBTL1 (0.64) | KMT2AGAASMN1; SMN2L3MBTL1MAPK1 | |
| SCHEMBL750886 | 0.81 | TRPV4 (0.73) | KMT2AUSP2GAAMEN1SMN1; SMN2 | |
| SCHEMBL5188196 | 0.81 | KMT2A (0.60) | KMT2AUSP2GAAMEN1SMN1; SMN2 | |
| SCHEMBL6039243 | 0.81 | KMT2A (0.60) | KMT2AUSP2GAAMEN1SMN1; SMN2 | |
| SCHEMBL1066283 | 0.81 | KMT2A (0.60) | KMT2AUSP2GAAMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| WO-2025136811-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | IDEAYA BIOSCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250145637-A1 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| US-20250122182-A1 | MYST Inhibitors | Isosterix, Inc. | 2025-04-17 | — | — | US | disclosed |
| EP-4385989-A1 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2024-06-19 | — | — | EP | disclosed |
| EP-4335439-A2 | COMPOUNDS | CTXT PTY LTD (AU) | 2024-03-13 | — | — | EP | disclosed |
| CN-117597341-A | Sulfonamide derivative, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| CN-113773242-B | Indol-2-one BRD4 inhibitor and preparation and application thereof | 兰州大学 | 2023-10-27 | — | — | CN | disclosed |
| US-5965490-A | NOVEL COMPOUNDS WITH IMPROVED SELECTIVITY TO VALUABLE CROPS AND IMPROVED TOXICOLOGICAL AND ENVIRONMENTAL ATTRIBUTES; APPLYING TO CONTROL WEEDS BY EITHER PREEMERGENCE OR POSTEMERGENCE APPLICATION | DOW AGROSCIENCES LLC (US) | 1999-10-12 | — | — | US | disclosed |
| WO-1999026926-A1 | HETEROARYL AMINOGUANIDINES AND ALKOXYGUANIDINES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| EP-0917528-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | Astra Aktiebolag (SE) | 1999-05-26 | — | — | EP | disclosed |
| US-5858924-A | N-( 1, 2, 4! triazoloazinyl) benzenesulfonamide and pyridinesulfonamide compounds and their use as herbicides | DOW AGROSCIENCES LLC (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0877745-A2 | N-( 1,2,4] TRIAZOLOAZINYL)BENZENESULFONAMIDE AND PYRIDINESULFONAMIDE COMPOUNDS AND THEIR USE AS HERBICIDES | Dow Agrosciences LLC (US) | 1998-11-18 | — | — | EP | disclosed |
| WO-1998013367-A1 | N-([1,2,4] TRIAZOLOAZINYL)BENZENESULFONAMIDE AND PYRIDINESULFONAMIDE COMPOUNDS AND THEIR USE AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 1998-04-02 | — | — | WO | disclosed |
| WO-1998001422-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1998-01-15 | — | — | WO | disclosed |
| US-4766241-A | LOWER ACUTE TOXICITY | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-08-23 | — | — | US | disclosed |
| US-4607030-A | ANTIEDEMICS, HYPOTENSIVES | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-08-19 | — | — | US | disclosed |
| EP-0088345-A2 | 2-Aminomethyl-6-sulfamoylphenol derivatives, process for their preparation, their use and pharmaceutical preparations based on these compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | KMT2A 3057/4885USP2 3303/4885GAA 3587/4885 |
| US-20250145637-A1 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SULT2A1, KAT8, TST | KMT2A 49/4885USP2 1044/4885GAA 461/4885 |
| US-20250122182-A1 | MYST Inhibitors | MNAT1, SUGT1, ACAT2 | KMT2A 161/4885USP2 466/4885GAA 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.